Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Notice for sotatercept (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
sotatercept
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
lyophilized powder for solution for injection
Indication
For the treatment of patients with Pulmonary Arterial Hypertension (PAH),
Therapeutic area
Cardiovascular